Figure 1.

Trametinib reduces basal and pazopanib-associated ERK activation in cultured DTC. CAL62 or BCPAP cells were treated 4 h or 5 days (as described in Materials and methods) with vehicle, trametinib 10 nM, pazopanib 800 nM, or the combination. Lysates were analyzed for pERK by immunoblotting. Control levels of total ERK and GAPDH are also shown. pERK was acutely and chronically upregulated by pazopanib in CAL62 cells in vitro, mitigated by combination with trametinib. DTC, differentiated thyroid cancer.